Article3 Biotech2026
A novel combinatorial therapeutic strategy using resveratrol and viral oncolysis for diffuse intrinsic pontine glioma: an in vitro study.
Article in 3 Biotech, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pediatric central nervous system (CNS) tumors, specifically Diffuse Midline Gliomas (DMG) are a leading cause of cancer-related deaths in children presenting an unmet need for novel therapeutic development. In this study, we assessed the combined effects of resveratrol (RSV) and the oncolytic herpes simplex virus (oHSV), hrR3 in patient-derived diffuse intrinsic pontine glioma (DIPG) cell lines. RSV or hrR3 monotherapy resulted in a dose- and time-dependent reduction in cell viability. RSV pretreatment followed by hrR3 infection led to a significantly greater reduction in tumor cell viability than monotherapy. RSV pretreatment further enhanced the replication of hrR3, as evidenced by increased viral titers. Mechanistic analysis showed that the combination therapy was associated with reduced phosphorylation of the signal transducer and activator of transcription 3 (STAT3) and protein kinase B (AKT) signaling pathways, along with increased expression of apoptotic markers, including cleaved caspase-3 and Poly (ADP-ribose) polymerase (PARP). Together these findings indicate that RSV potentiates hrR3-mediated oncolysis in DIPG cells by enhancing viral replication, suppressing survival signaling and promoting apoptosis in DIPG cells in vitro. Supplementary Information: The online version contains supplementary material available at 10.1007/s13205-026-05029-x.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.